What's Going On With Oscar Health Stock On Wednesday?

Oscar Health (OSCR) reported mixed Q2 results, with revenue of $2.86 billion and an $0.89 per share loss, both missing consensus estimates, and a medical loss ratio rising to 91.1%. Despite the Q2 misses, the company reaffirmed its fiscal 2025 sales guidance of $12 billion to $12.2 billion, exceeding Wall Street forecasts, and announced a strategic partnership with Hy-Vee for a new employer health insurance plan launching in late 2025. OSCR shares were down 7.73% on Wednesday, contrasting with a broader positive sentiment in the health insurance sector driven by recent high-profile investor positions in peers.

Analysis

Oscar Health (OSCR) presents a conflicting profile of near-term operational struggles against a bullish long-term growth outlook. The company's second-quarter results missed consensus on both the top and bottom lines, with revenue of $2.86 billion falling short of the $2.91 billion estimate and a loss per share of $0.89 wider than the expected $0.86. A significant point of concern is the deterioration in the medical loss ratio (MLR), which rose to 91.1% from 79.0% year-over-year, attributed to higher market morbidity. This signals a current challenge in managing claims costs. However, management has reaffirmed robust fiscal 2025 sales guidance of $12.0 billion to $12.2 billion, which notably exceeds the Wall Street consensus of $11.32 billion, and projects an improved MLR of 86%-87% for 2025. This guidance is supported by strategic initiatives such as the new partnership with Hy-Vee to enter the individual coverage health reimbursement arrangement (ICHRA) market, a tangible new growth channel. The market has reacted negatively to the Q2 performance, with the stock down 7.73%, suggesting investors are currently weighing the profitability miss more heavily than the strong forward guidance and strategic partnerships.

Key Decisions for Investors

• Investors should weigh the recent stock price decline, driven by the Q2 earnings miss and deteriorating medical loss ratio, against the company's strong 2025 revenue guidance which significantly surpasses consensus estimates.
• Closely monitor the company's progress in managing its medical loss ratio towards the guided 86%-87% range, as achieving this target is critical for its path to profitability in 2026.
• Consider the long-term growth potential from new strategic partnerships, like the Hy-Vee plan targeting the ICHRA market, as a key factor that could offset current operational headwinds.
• Note the divergence between OSCR's negative performance and the broader positive sentiment in the health insurance sector, which may present a relative value opportunity if management successfully executes on its guidance.